TRT During Surgery: What to Stop, When to Restart, and Everything Else You Need to Know

Testosterone replacement therapy (TRT) refers to prescription testosterone, most often testosterone cypionate or testosterone enanthate injections, transdermal gels (1% or 1.62%), or subcutaneous pellets, used to treat diagnosed hypogonadism. There is no single FDA-mandated protocol for managing TRT around surgery. What follows is drawn from an Endocrine Society clinical practice guideline on hypogonadism management, observational surgical data, and common anesthesia practice patterns, not from a surgery-specific label or a dedicated perioperative guideline. That distinction matters, because it means your surgical team's exact timeline may reasonably differ from what is described here.

The useful question is not "should I stop TRT before surgery" but "what is my hematocrit, and does my specific surgery carry high enough clotting risk to justify a pause." Men with a normal hematocrit going into a low-VTE-risk procedure may need little more than a short heads-up to their anesthesiologist. Men with hematocrit near or above 54%, or those facing a high-VTE procedure like joint replacement, need a real conversation about pausing therapy and possibly checking labs again before the operating room.

The core answer, in one place

Most surgical teams ask men on TRT to pause injections or gels for roughly 10 to 14 days before an elective procedure, mainly because testosterone stimulates red blood cell production and elevated hematocrit is linked to higher clotting risk under the immobility and vessel trauma of surgery. This interval is common clinical practice rather than a formal requirement from a testosterone-specific surgical guideline. The Endocrine Society's 2018 clinical practice guideline on hypogonadism recommends checking hematocrit periodically and stopping testosterone therapy if it exceeds 54%, though that guidance was written for routine monitoring, not specifically for surgical timing.[1] TRT can typically restart 24 to 72 hours after surgery once a physician confirms there is no active bleeding, though higher-VTE procedures may call for a longer pause.

Why hematocrit is the central concern

Testosterone increases erythropoietin secretion from the kidney, which drives red blood cell production. A meaningful subset of men on TRT develop polycythemia, generally defined as hematocrit above 54%. The Endocrine Society guideline addresses this by recommending baseline hematocrit testing, rechecks at 3 to 6 months and then annually, and discontinuation of testosterone if hematocrit exceeds 54%.[1]

Elevated hematocrit thickens blood. A retrospective cohort study published in JAMA Surgery examined a large surgical population and reported an association between pre-operative polycythemia and increased 30-day venous thromboembolism (VTE) events.[2] The exact magnitude of that association, and how directly it applies to TRT-induced polycythemia specifically (as opposed to polycythemia from other causes), needs direct verification against the original paper before being cited as a precise number. What can be stated with more confidence is the direction of the relationship: higher hematocrit before surgery is a recognized VTE risk factor, and TRT is a known cause of secondary polycythemia.

Human erythropoietic pharmacology gives a rough sense of why the pause matters at all. Testosterone cypionate has an elimination half-life of roughly 8 days, so a skipped injection meaningfully lowers circulating testosterone within about two weeks. Red blood cells, by contrast, live around 120 days, so stopping TRT for two weeks will not fully normalize an already-elevated hematocrit. It does, however, stop the drug from stimulating further red cell production during the window that matters most for surgery. A controlled dosing study in healthy men found that testosterone increases red cell mass in a dose-dependent way over weeks of treatment, which is the mechanistic basis for periodic hematocrit monitoring on TRT, though the exact percentage-point rise you should expect varies by individual and needs your own lab trend, not a generic number.[3]

Topical gels clear faster than injections. Serum testosterone from gel formulations trends back toward baseline within roughly 96 hours of stopping, which is why some clinicians allow a shorter 5 to 7 day pause for gel users. Confirm this with your prescribing physician and your surgical team rather than assuming it applies to your case.

What happens if you stop TRT abruptly

Stopping TRT abruptly is not acutely dangerous for most men, but it is not comfortable. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis, meaning your pituitary has reduced its own output of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). When the external testosterone disappears, that axis does not switch back on immediately.

A study following men after TRT cessation found that recovery of baseline LH and total testosterone took weeks to months, with meaningful individual variation depending on how long a man had been on therapy.[4] Men on TRT for under a year tend to recover faster than men with longer treatment histories. This recovery timeline research describes stopping therapy altogether, not a short surgical pause, so it should be read as background on how the HPG axis behaves rather than a direct prediction for a two-to-three week gap.

During a short pre-surgical pause, men commonly report:

• Fatigue and reduced motivation, often starting within 7 to 10 days
• Decreased libido and softer erections within the first two weeks
• Mild irritability or low mood
• Loss of muscle "fullness," which is mostly water and glycogen shifts rather than actual muscle loss over such a short window

Men with primary hypogonadism (testicular failure, no endogenous reserve) tend to feel a pause more acutely than men with secondary hypogonadism, because they have no backup production to soften the drop.

What is established, what is plausible, and what is not established

Established: Testosterone therapy raises hematocrit in a dose-dependent way, and periodic hematocrit monitoring with a stop-threshold around 54% is part of Endocrine Society guidance for TRT overall.[1] Elevated hematocrit is a recognized general risk factor for perioperative VTE.

Plausible but not rigorously proven for this exact scenario: That a fixed 10 to 14 day pre-operative pause meaningfully lowers surgical VTE risk specifically caused by TRT, as opposed to general polycythemia from any cause. No dedicated randomized trial answers this question directly for TRT patients undergoing surgery.

Not established: Any single "safe" hematocrit cutoff or pause length that applies uniformly across formulations, surgery types, and individual VTE risk profiles. Pellet users cannot pause therapy at all once implanted, and their management depends entirely on hematocrit optimization and VTE prophylaxis rather than timing a stop.

How fast TRT benefits return after restarting

Libido and sexual function. In the Testosterone Trials (TTrials), a set of placebo-controlled trials across 12 U.S. sites in 790 men aged 65 and older, sexual activity scores improved significantly compared to placebo by 12 weeks of continuous treatment.[5] After a short surgical pause, many men notice libido returning within roughly 2 to 4 weeks of restarting, as levels climb back into a therapeutic range, though this specific post-pause timeline is inferred from the general trial timeline rather than a study of surgical interruption itself.

Energy and mood. These often track slightly ahead of libido changes in clinical experience, but there is no dedicated trial isolating this exact timeline after a brief pause and restart, so treat any specific week-count here as a general expectation rather than a proven figure.

Body composition. Lean mass changes take longer than libido or mood changes to become measurable. Existing randomized evidence on testosterone's effects on body composition generally requires several months of continuous treatment before differences reach statistical significance; a brief 2 to 3 week interruption will not erase prior gains, but new anabolic signaling effectively restarts. A specific week-range for this claim needs to be checked against the correct meta-analysis before being stated as an exact number, since the reference some sources use for this figure is actually a bone-health meta-analysis, not a lean-mass timeline study, and should not be cited as if it were.[6]

Hematocrit. This tends to rise again relatively quickly once therapy resumes. Men who ran elevated hematocrit before their pause are reasonable candidates for a follow-up complete blood count roughly 6 weeks after restarting, so a new problem is caught before it becomes a repeat surgical issue.

A perioperative TRT decision framework

This is a general decision aid, not individualized medical advice. Your surgeon, anesthesiologist, and prescribing physician make the final call based on your labs, your surgery, and your full medical history.

Failure modes to watch for: assuming a "pause" applies to pellets (it does not), assuming a normal hematocrit rules out surgical risk from TRT (it does not address OSA or cardiovascular history), and restarting injections on your own timeline without your surgeon's sign-off simply because two weeks have passed.

Alcohol around TRT and surgery

Alcohol complicates TRT management around surgery in two separate ways. First, alcohol suppresses testosterone production, both by dampening pituitary LH pulsatility and by increasing conversion of testosterone to estradiol in the liver. An older experimental study in normal human males found that a single moderate dose of alcohol acutely lowered serum testosterone, with suppression lasting several hours.[7] This is a small, decades-old study, and the exact percentage of suppression it reported should be treated as illustrative of the mechanism rather than a number to rely on precisely.

Second, alcohol independently raises surgical risk. Chronic use impairs platelet function and reduces hepatic synthesis of clotting factors, which increases bleeding risk. Standard pre-operative instructions typically already ask patients to avoid alcohol for at least 48 hours before a procedure. For men managing TRT-related hematocrit around surgery, extending that window further, and avoiding alcohol entirely during active recovery given interactions with opioids and acetaminophen, is a reasonable and low-cost precaution.

Supplements that need pre-op disclosure

Several supplements commonly stacked with TRT carry documented perioperative bleeding risk. A widely cited JAMA review of herbal medicines and perioperative care lists several of these mechanisms and recommends disclosure and, for some agents, discontinuation before surgery.[8]

• Fish oil (omega-3s): high doses have antiplatelet effects; many anesthesia teams ask patients to pause high-dose fish oil roughly 7 to 10 days before surgery. Standard 1-gram daily doses are generally considered lower risk but still worth mentioning.
• Vitamin E: supplemental doses of 400 IU or more can inhibit platelet aggregation and prolong bleeding time; a similar 7 to 10 day pause is reasonable.
• Saw palmetto: commonly used alongside TRT for prostate symptoms; case reports have linked it to increased intraoperative bleeding, so a longer pause (commonly around 14 days) is often advised.
• Zinc: doses above the NIH Office of Dietary Supplements' tolerable upper intake level can impair copper absorption and red-cell function over time; disclose your dose.[9]
• Ashwagandha: a randomized trial in resistance-trained men found that ashwagandha root extract raised testosterone over 8 weeks of use.[10] No major bleeding interaction is documented, but its mild effect on cortisol could theoretically interact with the stress response to anesthesia, so disclosure is still worthwhile.
• Creatine: no known bleeding risk, but it can transiently raise serum creatinine, which may be misread as a kidney function problem if your anesthesia team is not told you take it.
• DHEA: partially converts to testosterone and estrogen but is far less potent than pharmaceutical testosterone. It is not an adequate substitute for TRT during a surgical pause.

What matters to your anesthesia team beyond hematocrit

Sleep apnea. Testosterone therapy can worsen obstructive sleep apnea (OSA) in susceptible men. One placebo-controlled randomized trial in obese men with severe OSA found that testosterone therapy worsened apnea-hypopnea measures compared to placebo.[11] This is a single trial in a specific population (obese men with pre-existing severe OSA), not a broad meta-analysis, so the finding should not be generalized to all men on TRT without that caveat. OSA raises the risk of post-operative respiratory depression under opioid analgesia, which is why disclosing TRT use matters even when hematocrit looks normal.

Cardiovascular history. The TRAVERSE trial, a large randomized trial (N=5,246) in middle-aged and older men with hypogonadism and elevated cardiovascular risk, found that testosterone therapy did not increase major adverse cardiac events compared to placebo over a median follow-up of about 33 months.[12] That finding addresses long-term cardiovascular safety of ongoing therapy, not the separate question of perioperative risk in a man with recent cardiac events. Men with a recent heart attack, stroke, or uncontrolled heart failure should have their surgical clearance timeline coordinated with a cardiologist, independent of the TRT question.

Polycythemia vera versus TRT-related polycythemia. If hematocrit was elevated before starting TRT, or climbs above roughly 56% on therapy, some anesthesiologists request a hematology consult to rule out primary polycythemia vera, which carries its own separate management protocol distinct from TRT-related secondary polycythemia.

Restarting after surgery

Most elective procedures allow TRT to restart 24 to 72 hours post-operatively once there is no active bleeding, no unplanned return to the operating room, and physician confirmation that resuming is appropriate. Higher-VTE procedures, such as major joint replacement or abdominal surgery, may call for a longer pause of two to four weeks, particularly alongside chemical VTE prophylaxis such as low-molecular-weight heparin.

If you are on anticoagulation when you restart, ask whether subcutaneous injection is a reasonable alternative to intramuscular injection, since intramuscular injections carry a higher hematoma risk on blood thinners. Get explicit documented clearance from your surgeon before resuming any testosterone formulation.

This article is for general education and does not replace individualized guidance from your prescribing physician, surgeon, and anesthesiologist, who can weigh your specific labs, surgery type, and medical history. If you experience unexpected bleeding, severe shortness of breath, chest pain, or calf swelling and pain after surgery, seek urgent medical care rather than waiting for a scheduled follow-up.